{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T19:52:03Z","timestamp":1788205923732,"version":"build-2803163510"},"reference-count":58,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T00:00:00Z","timestamp":1263945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:p><jats:bold>Aim:\u2002<\/jats:bold> The aim of the present study was to evaluate demographics, clinical features, psychiatric diagnoses and prognosis of neuroleptic malignant syndrome (NMS) reported in Turkey, and to assess their association with mortality.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Data on all reported cases of NMS in the Turkish Psychiatric Index between 1985 and 2005 were collected. The type, dosage and administration period of neuroleptics, the clinical and laboratory findings; and prognosis were compared in terms of mortality.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Thirty\u2010six patients with a mean age of 33.67\u2003\u00b1\u200316.98\u2003years were identified. Fifteen (41.7%) were diagnosed as having schizophrenia or other psychotic disorders and the same number were diagnosed as having affective disorder. Remaining five (13.9%) were diagnosed with other psychiatric disorders and 1 (2.7%) had no psychiatric diagnosis. Twenty\u2010two (61.1%) of the NMS cases were associated with high potency typical neuroleptics. Association between an atypical antipsychotic and NMS has been reported in one case. NMS appeared within 7\u2003days after initiation of the antipsychotic medication in the majority of samples (<jats:italic>n<\/jats:italic>\u2003=\u200319, 52.8%). Several combinations of rescue treatments were used in the majority of cases (<jats:italic>n<\/jats:italic>\u2003=\u200319, 52.8%), although bromocriptine (<jats:italic>n<\/jats:italic>\u2003=\u200322, 61.1%) was the most frequently preferred rescue treatment for NMS. Benzodiazepines were significantly better than the other treatment options in preventing mortality. Five out of the 36 patients (13.9%) with NMS had died. Age was the only significant independent factor that was associated with mortality.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Benzodiazepines may be included in the treatment of NMS. The mortality rate due to NMS in Turkey was lower than the previously reported rates from other developing countries.<\/jats:p>","DOI":"10.1111\/j.1440-1819.2009.02042.x","type":"journal-article","created":{"date-parts":[[2010,1,21]],"date-time":"2010-01-21T01:12:13Z","timestamp":1264036333000},"page":"79-87","source":"Crossref","is-referenced-by-count":42,"title":["Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death"],"prefix":"10.1111","volume":"64","author":[{"given":"\u00dcmit","family":"Tural","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emin","family":"\u00d6nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"79","article-title":"The neuroleptic malignant syndrome","volume":"41","author":"Caroff SN","year":"1980","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.12.1587"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(87)90010-2"},{"key":"e_1_2_5_5_2","first-page":"352","article-title":"Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital","volume":"50","author":"Keck PE","year":"1989","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02195723"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(00)00402-8"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.147.9.1149"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(99)90071-8"},{"key":"e_1_2_5_10_2","first-page":"111","article-title":"Neuroleptic malignant syndrome in Mexico","volume":"10","author":"Montoya A","year":"2003","journal-title":"Can. J. Clin. Pharmacol."},{"key":"e_1_2_5_11_2","first-page":"245","article-title":"Neuroleptic malignant syndrome in a general hospital psychiatry clinic","volume":"1","author":"\u00d6nder ME","year":"1990","journal-title":"Turk. Psikiyatri. Derg."},{"key":"e_1_2_5_12_2","first-page":"121","article-title":"Neuroleptic malignant syndrome an analysis of 9 cases","volume":"94","author":"Rivera JM","year":"1990","journal-title":"Med. Clin. (Barc)"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.161.2.254"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810100056011"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.142.10.1137"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.146.6.717"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-198804000-00007"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2003.02385.x"},{"key":"e_1_2_5_19_2","first-page":"38","article-title":"Neuroleptic malignant syndrome: A case report","volume":"11","author":"Alpay N","year":"1998","journal-title":"D\u00fcs\u00fcnen Adam"},{"key":"e_1_2_5_20_2","first-page":"61","article-title":"Two cases of neuroleptic malignant syndrome","volume":"4","author":"Arkona\u00e7 O","year":"1991","journal-title":"D\u00fcs\u00fcnen Adam"},{"key":"e_1_2_5_21_2","first-page":"20","article-title":"Neuroleptic malignant syndrome: A case report","volume":"1","author":"Arpac\u0131 B","year":"1986","journal-title":"D\u00fcs\u00fcnen Adam"},{"key":"e_1_2_5_22_2","first-page":"377","volume-title":"Proceedings of the 4th International Symposium on Recent Developments of Clinical Psychopharmacology","author":"Ask\u0131n R","year":"1998"},{"key":"e_1_2_5_23_2","first-page":"58","volume-title":"Proceedings of the XXVIII National Congress of Psychiatry","author":"Ayd\u0131n N","year":"1992"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2003.07.001"},{"key":"e_1_2_5_25_2","first-page":"131","article-title":"Neuroleptic malignant syndrome","volume":"12","author":"Erisik K","year":"1992","journal-title":"Haseki T\u0131p B\u00fclteni"},{"key":"e_1_2_5_26_2","first-page":"229","article-title":"A case with neuroleptic malignant syndrome","volume":"69","author":"Ery\u00fcce \u00d6","year":"1994","journal-title":"Dirim"},{"key":"e_1_2_5_27_2","first-page":"40","article-title":"Neuroleptic malignant syndrome","volume":"2","author":"Gedizoglu M","year":"1987","journal-title":"N\u00f6rolojik Bilimler Dergisi"},{"key":"e_1_2_5_28_2","unstructured":"G\u00fcneyM Akbostanc\u0131C.Neuroleptic malign syndrome. Poster presented at XXVI. Congress of National Psychiatry and Neurology Proceedings book.1990;129\u2013130(in Turkish)."},{"key":"e_1_2_5_29_2","first-page":"120","article-title":"Neuroleptic malignant syndrome: 5 cases","volume":"2","author":"Herken H","year":"1998","journal-title":"Klinik Psikiyatri"},{"key":"e_1_2_5_30_2","first-page":"911","article-title":"A case of neuroleptic malignant syndrome","volume":"3","author":"Is\u0131k N","year":"1990","journal-title":"Klinik Gelisim"},{"key":"e_1_2_5_31_2","first-page":"545","volume-title":"Proceedings of the 40th National Congress of Psychiatry","author":"Orhan O","year":"2004"},{"key":"e_1_2_5_32_2","first-page":"267","article-title":"Neuroleptic malign syndrome","volume":"43","author":"\u00d6kten F","year":"1998","journal-title":"Ankara T\u0131p Mecmuas\u0131"},{"key":"e_1_2_5_33_2","first-page":"226","article-title":"Could catatonia be the predictor of neuroleptic malignant syndrome: A case report","volume":"5","author":"\u00d6nder ME","year":"1994","journal-title":"Turk Psikiyatri Derg"},{"key":"e_1_2_5_34_2","first-page":"203","article-title":"ECT in the treatment of NMS","volume":"1","author":"\u00d6nder ME","year":"1990","journal-title":"Turk Psikiyatri Derg"},{"key":"e_1_2_5_35_2","first-page":"43","article-title":"Neuroleptic malignant syndrome developed on normal pressure hydrocephalus","volume":"8","author":"S\u0131r A","year":"1998","journal-title":"Klin. Psikofarmakol. B\u00fclteni"},{"key":"e_1_2_5_36_2","first-page":"935","volume-title":"Proceedings of the XXIV National Congress of Psychiatry and Neurology","author":"S\u00fcrmeli A","year":"1988"},{"key":"e_1_2_5_37_2","first-page":"929","volume-title":"Proceedings of the XXIV National Congress of Psychiatry and Neurology","author":"\u015eenol S","year":"1988"},{"key":"e_1_2_5_38_2","first-page":"258","article-title":"Neuroleptic malignant syndrome: Two cases","volume":"4","author":"Turhan G","year":"1989","journal-title":"G\u00f6ztepe Hastanesi T\u0131p B\u00fclteni"},{"key":"e_1_2_5_39_2","first-page":"505","article-title":"Fever and altered consciousness are not always equal to central nervous system infection: Neuroleptic malignant syndrome in a 15\u2010year\u2010old girl","volume":"38","author":"\u00dcnal F","year":"1996","journal-title":"Turk. J. Pediatr."},{"key":"e_1_2_5_40_2","first-page":"217","volume-title":"Proceedings of the XXVII National Congress of Psychiatry","author":"\u00dcnal F","year":"1991"},{"key":"e_1_2_5_41_2","first-page":"115","article-title":"Neuroleptic malignant syndrome: A case report and review of literature","volume":"13","author":"Yalu\u011f \u0130","year":"2005","journal-title":"3P Dergisi"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.2003.01220.x"},{"key":"e_1_2_5_43_2","first-page":"126","article-title":"Single dose chlorpromazine induced neuroleptic malignant syndrome responded to ECT: A case report","volume":"7","author":"Yumru M","year":"2005","journal-title":"T\u00fcrkiyede Psikiyatri"},{"key":"e_1_2_5_44_2","first-page":"151","article-title":"Neuroleptic malignant syndrome associated with thyrotoxic crisis: A case report","volume":"31","author":"Zoroglu S","year":"1994","journal-title":"N\u00f6ropsikiyatri Arsivi"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198610000-00002"},{"key":"e_1_2_5_46_2","first-page":"160","article-title":"The use of antipyschotic prescription for an university psychiatry clinic: A retrospective study","volume":"16","author":"Say\u0131n A","year":"2006","journal-title":"Klin. Psikofarmakol. B\u00fclteni"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.2.132"},{"key":"e_1_2_5_48_2","first-page":"344","article-title":"Treatment of neuroleptic malignant syndrome with dantrolene sodium","volume":"139","author":"Coons DJ","year":"1982","journal-title":"Am. J. Psychiatry"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.145.5.617"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.161.2.257"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00109-7"},{"key":"e_1_2_5_52_2","first-page":"1137","article-title":"Neuroleptic malignant syndrome: Fatalities associated with neuroleptic use and schizophrenia","volume":"142","author":"Straker M","year":"1985","journal-title":"Psychiatry J. Univ. Ottowa"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1987.tb02944.x"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.140.12.1619"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1988.tb06355.x"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1987.tb02782.x"},{"key":"e_1_2_5_57_2","first-page":"378","article-title":"Specific treatment of the neuroleptic malignant syndrome","volume":"44","author":"Caroff SN","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"e_1_2_5_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199211000-00028"},{"key":"e_1_2_5_59_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900013407"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1819.2009.02042.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1819.2009.02042.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T04:12:20Z","timestamp":1697256740000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1819.2009.02042.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1111\/j.1440-1819.2009.02042.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1819.2009.02042.x","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,20]]}}}